CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation

References

• Eng FJ, Friedman SL, Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol-Gastr L. 2000;279(1):G7–G11.
   PubMed Web of Science ®Google Scholar
• Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence-based treatment. World J Gastroenterol. 2014;20(18):5442–5460. doi:10.3748/wjg.v20.i18.544224833875
   PubMed Web of Science ®Google Scholar
• Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593–608. doi:10.1016/j.jhep.2012.12.00523419824
   PubMed Web of Science ®Google Scholar
• Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013;5(167):167sr161–167sr161. doi:10.1126/scitranslmed.3004700
   Web of Science ®Google Scholar
• Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Seminars in liver disease. 2001;21(3):351-372. doi:10.1055/s-2001-17556
   Google Scholar
• Reeves HL, Friedman SL. Activation of hepatic stellate cells—a key issue in liver fibrosis. Front Biosci. 2002;7(4):808–826. doi:10.2741/reeves
   Google Scholar
• Altamirano-Barrera A, Barranco-Fragoso B, Mendez-Sanchez N. Management strategies for liver fibrosis. Ann Hepatol. 2017;16(1):48–56. doi:10.5604/16652681.122681428051792
   PubMed Web of Science ®Google Scholar
• Iimuro Y, Brenner DA. Matrix Metalloproteinase gene delivery for liver fibrosis. Pharm Res-Dordr. 2008;25(2):249–258. doi:10.1007/s11095-007-9311-7
   PubMed Web of Science ®Google Scholar
• Siller-Lopez F, Sandoval A, Salgado S, et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology. 2004;126(4):1122–1133; discussion 1949.
   PubMed Web of Science ®Google Scholar
• Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26(4):431–442. doi:10.1038/nbt139618376398
   PubMed Web of Science ®Google Scholar
• Sobrevals L, Enguita M, Rodriguez C, et al. AAV vectors transduce hepatocytes in vivo as efficiently in cirrhotic as in healthy rat livers. Gene Ther. 2012;19(4):411–417. doi:10.1038/gt.2011.11921850051
   PubMedGoogle Scholar
• Kamimura K, Kanefuji T, Yokoo T, et al. Safety assessment of liver-targeted hydrodynamic gene delivery in dogs. PLoS One. 2014;9(9):e107203. doi:10.1371/journal.pone.010720325251246
   PubMedGoogle Scholar
• Terai S, Tanimoto H, Maeda M, et al. Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy. J Gastroenterol. 2012;47(5):491–497. doi:10.1007/s00535-012-0580-522488349
   PubMedGoogle Scholar
• Garcia-Guerra A, Dunwell TL, Trigueros S. Nano-scale gene delivery systems: current technology, obstacles, and future directions. Curr Med Chem. 2018;25(21):2448–2464. doi:10.2174/092986732566618010810072329308734
   PubMedGoogle Scholar
• Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-able and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22(7):2214–2222. doi:10.1096/fj.07-10562718326784
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheumatol. 2009;60(1):219–224. doi:10.1002/art.24186
   PubMedGoogle Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. New Engl J Med. 2006;354(25):2655–2666. doi:10.1056/NEJMoa05512016790698
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. New Engl J Med. 2006;354(25):2655–2666. doi:10.1056/NEJMoa05512016790698
   PubMedGoogle Scholar
• Rankin AL, Mumm JB, Murphy E, et al. IL-33 induces IL-13–dependent cutaneous fibrosis. J Immunol. 2010;184(3):1526–1535. doi:10.4049/jimmunol.090330620042577
   PubMed Web of Science ®Google Scholar
• Li Z, Wei W, Chen B, et al. The effect of rhCygb on CCl 4-induced hepatic fibrogenesis in rat. Sci Rep-Uk. 2016;6:23508. doi:10.1038/srep23508
   PubMed Web of Science ®Google Scholar
• Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis. 2008;12(4):939–962, xi. doi:10.1016/j.cld.2008.07.01118984475
   PubMed Web of Science ®Google Scholar
• Inagaki Y, Higashiyama R, Higashi K. Novel anti-fibrotic modalities for liver fibrosis: molecular targeting and regenerative medicine in fibrosis therapy. J Gastroenterol Hepatol. 2012;27 Suppl 2:85–88. doi:10.1111/j.1440-1746.2011.07006.x22320923
   PubMedGoogle Scholar
• Rosenbloom J, Mendoza FA, Jimenez SA. Strategies for anti-fibrotic therapies. Biochim Biophys Acta. 2013;1832(7):1088–1103. doi:10.1016/j.bbadis.2012.12.00723266403
   PubMed Web of Science ®Google Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi:10.1056/NEJMoa140258224836312
   PubMed Web of Science ®Google Scholar
• Meyer KC, Danoff SK, Lancaster LH, Nathan SD. Management of idiopathic pulmonary fibrosis in the elderly patient: addressing key questions. Chest. 2015;148(1):242–252. doi:10.1378/chest.14-247526149553
   PubMed Web of Science ®Google Scholar
• King CS, Nathan SD. Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2015;21(5):479–489. doi:10.1097/MCP.000000000000019026164298
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: recent advances in pharmacological therapy. Pharmacol Ther. 2015;152:18–27. doi:10.1016/j.pharmthera.2015.04.00525946646
   PubMed Web of Science ®Google Scholar
• Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3(1):16.20809935
   PubMedGoogle Scholar
• Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Inv Drug. 2010;19(2):275–283. doi:10.1517/13543780903501539
   PubMed Web of Science ®Google Scholar
• Jose A, Mandapalli PK, Venuganti VVK. Liposomal hydrogel formulation for transdermal delivery of pirfenidone. J Liposome Res. 2016;26(2):139–147. doi:10.3109/08982104.2015.106061126114208
   PubMed Web of Science ®Google Scholar
• Li D, Gong L. Preparation of novel pirfenidone microspheres for lung-targeted delivery: in vitro and in vivo study. Drug Des Devel Ther. 2016;10:2815–2821. doi:10.2147/DDDT.S113670
   PubMed Web of Science ®Google Scholar
• Rasooli R, Rajaian H, Pardakhty A, Mandegary A. Preference of aerosolized pirfenidone to oral intake: an experimental model of pulmonary fibrosis by paraquat. J Aerosol Med Pulm Drug Deliv. 2018;31(1):25–32. doi:10.1089/jamp.2016.134228696894
   PubMed Web of Science ®Google Scholar
• Meng H, Xu Y. Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation. Drug Des Devel Ther. 2015;9:3369–3376.
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13–19. doi:10.1016/j.ejps.2014.02.01424613900
   PubMed Web of Science ®Google Scholar
• Meyer KC, Decker CA. Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag. 2017;13:427–437. doi:10.2147/TCRM.S8114128435277
   PubMed Web of Science ®Google Scholar
• Bando M, Yamauchi H, Ogura T, et al. Clinical experience of the long-term use of pirfenidone for idiopathic pulmonary fibrosis. Intern Med. 2016;55(5):443–448. doi:10.2169/internalmedicine.55.527226935361
   PubMed Web of Science ®Google Scholar
• Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair. 2010;3(1):1–11.20047646
   PubMedGoogle Scholar
• Li Z, Liu X, Wang B, et al. Pirfenidone suppresses MAPK signaling pathway to reverse epithelial‐mesenchymal transition and renal fibrosis. Nephrology. 2017;22(8):589–597. doi:10.1111/nep.1283127245114
   PubMed Web of Science ®Google Scholar
• Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12(4):446. doi:10.1038/nm138816565722
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829. doi:10.1183/09031936.0000520919996196
   PubMed Web of Science ®Google Scholar
• Lasky J. Pirfenidone. Idrugs. 2004;7(2):166–172.15057662
   PubMed Web of Science ®Google Scholar
• Kanzler S, Lohse AW, Keil A, et al. TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol-Gastr L. 1999;276(4):G1059–G1068.
   PubMed Web of Science ®Google Scholar
• Chen MH, Chen JC, Tsai CC, et al. The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-Saiko-to in rat‘s bile duct ligated model. J Ethnopharmacol. 2005;97(1):7–13. doi:10.1016/j.jep.2004.09.04015652268
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Arai T, Mori M, et al. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2002;283(1):L103–L112. doi:10.1152/ajplung.00187.200112060566
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang Y, Reiberger T, et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014;59(4):1435–1447. doi:10.1002/hep.2679024242874
   PubMed Web of Science ®Google Scholar
• Wald O, Pappo O, Safadi R, et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol. 2004;34(4):1164–1174. doi:10.1002/eji.20032444115048728
   PubMed Web of Science ®Google Scholar
• Fruehauf S. Current clinical indications for plerixafor. Transfus Med Hemother. 2013;40(4):246–250. doi:10.1159/00035422924415962
   PubMedGoogle Scholar
• De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacol Ther. 2010;128(3):509–518. doi:10.1016/j.pharmthera.2010.08.00920826182
   PubMedGoogle Scholar
• Liesveld JL, Bechelli J, Rosell K, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res. 2007;31(11):1553–1563. doi:10.1016/j.leukres.2007.02.01717403536
   PubMedGoogle Scholar
• Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201(8):1307–1318. doi:10.1084/jem.2004138515837815
   PubMed Web of Science ®Google Scholar
• Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010;7(8):425–436. doi:10.1038/nrgastro.2010.9720585339
   PubMed Web of Science ®Google Scholar
• Lin TT, Gao DY, Liu YC, et al. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. J Control Release. 2016;221:62–70. doi:10.1016/j.jconrel.2015.11.00326551344
   PubMed Web of Science ®Google Scholar
• Makino H, Aono Y, Azuma M, et al. Antifibrotic effects of a CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J Med Invest. 2013;60(1–2):127–137.23614921
   PubMedGoogle Scholar
• de Nigris F, Schiano C, Infante T, Napoli C. CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012;7(3):251–264.22376154
   PubMed Web of Science ®Google Scholar
• Welschinger R, Liedtke F, Basnett J, et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol. 2013;41(3):293–302.e291. doi:10.1016/j.exphem.2012.11.00423178377
   PubMed Web of Science ®Google Scholar
• Mei L, Liu Y, Zhang Q, Gao H, Zhang Z, He Q. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin. J Control Release. 2014;196:324–331. doi:10.1016/j.jconrel.2014.10.01725450404
   PubMed Web of Science ®Google Scholar
• Liu C-H, Chan K-M, Chiang T, et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis. Mol Pharm. 2016;13(7):2253–2262. doi:10.1021/acs.molpharmaceut.5b0091327224003
   PubMedGoogle Scholar
• Liu CH, Chan KM, Chiang T, et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis. Mol Pharm. 2016;13(7):2253–2262. doi:10.1021/acs.molpharmaceut.5b0091327224003
   PubMedGoogle Scholar
• Hu K, Zhou H, Liu Y, et al. Hyaluronic acid functional amphipathic and redox-responsive polymer particles for the co-delivery of doxorubicin and cyclopamine to eradicate breast cancer cells and cancer stem cells. Nanoscale. 2015;7(18):8607–8618. doi:10.1039/c5nr01084e25898852
   PubMedGoogle Scholar
• Zhang P, Li J, Ghazwani M, et al. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials. 2015;67:104–114. doi:10.1016/j.biomaterials.2015.07.02726210177
   PubMed Web of Science ®Google Scholar
• Wu J, Tang C, Yin C. Co-delivery of doxorubicin and interleukin-2 via chitosan-based nanoparticles for enhanced antitumor efficacy. Acta Biomater. 2017;47:81–90. doi:10.1016/j.actbio.2016.10.01227729232
   PubMed Web of Science ®Google Scholar
• Xiao B, Si X, Han MK, Viennois E, Zhang M, Merlin D. Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B. 2015;3(39):7724–7733.26617985
   PubMed Web of Science ®Google Scholar
• Madrigal-Carballo S, Lim S, Rodriguez G, et al. Biopolymer coating of soybean lecithin liposomes via layer-by-layer self-assembly as a novel delivery system for ellagic acid. J Funct Foods. 2010;2(2):99–106. doi:10.1016/j.jff.2010.01.002
   Web of Science ®Google Scholar
• Park SN, Jo NR, Jeon SH. Chitosan-coated liposomes for enhanced skin permeation of resveratrol. J Ind Eng Chem. 2014;20(4):1481–1485. doi:10.1016/j.jiec.2013.07.035
   Web of Science ®Google Scholar
• Meng S, Su B, Li W, et al. Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med Oncol. 2011;28(4):1180–1187. doi:10.1007/s12032-010-9621-120645030
   PubMedGoogle Scholar
• Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med. 2014;2(11):933–942. doi:10.1016/S2213-2600(14)70232-225439569
   PubMed Web of Science ®Google Scholar
• Zevon M, Ganapathy V, Kantamneni H, et al. CXCR-4 targeted, Short Wave Infrared (SWIR) emitting nanoprobes for enhanced deep tissue imaging and micrometastatic cancer lesion detection. Small. 2015;11(47):6347–6357. doi:10.1002/smll.20150220226514367
   PubMed Web of Science ®Google Scholar
• Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, Mura P. Preparation and characterization of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery. Int J Pharm. 2005;298(1):55–67. doi:10.1016/j.ijpharm.2005.03.03315941634
   PubMedGoogle Scholar
• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–252.5859039
   PubMed Web of Science ®Google Scholar
• Wei M, Xu Y, Zou Q, et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur J Pharm Sci. 2012;46(3):131–141. doi:10.1016/j.ejps.2012.02.00722369856
   PubMedGoogle Scholar
• Guo G, Kuai D, Cai S, et al. Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration, and invasion. PLoS One. 2013;8(4):e61206. doi:10.1371/journal.pone.006120623613813
   PubMedGoogle Scholar
• Bicho A, Peça IN, Roque A, Cardoso MM. Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8. Int J Pharm. 2010;399(1–2):80–86. doi:10.1016/j.ijpharm.2010.08.00520696228
   PubMed Web of Science ®Google Scholar
• Simard P, Leroux J-C. pH-sensitive immunoliposomes are specific to the CD33 cell surface antigen of leukemic cells. Int J Pharm. 2009;381(2):86–96. doi:10.1016/j.ijpharm.2009.05.01319446624
   PubMedGoogle Scholar
• Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37. doi:10.1038/nature0145112621426
   PubMed Web of Science ®Google Scholar
• Li H, Wang K, Yang X, et al. Dual-function nanostructured lipid carriers to deliver IR780 for breast cancer treatment: anti-metastatic and photothermal anti-tumor therapy. Acta Biomater. 2017;53:399–413. doi:10.1016/j.actbio.2017.01.07028159715
   PubMed Web of Science ®Google Scholar
• Mohammed A, Weston N, Coombes A, Fitzgerald M, Perrie Y. Liposome formulation of poorly water-soluble drugs: optimization of drug loading and ESEM analysis of stability. Int J Pharm. 2004;285(1–2):23–34. doi:10.1016/j.ijpharm.2004.07.01015488676
   PubMed Web of Science ®Google Scholar
• Dong Y, Feng -S-S. Methoxy poly (ethylene glycol)-poly (lactide)(MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials. 2004;25(14):2843–2849. doi:10.1016/j.biomaterials.2003.09.05514962562
   PubMedGoogle Scholar
• Li J, Zhu Y, Hazeldine ST, Li C, Oupický D. Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion. Angew Chem Int Ed Engl. 2012;51(35):8740–8743. doi:10.1002/anie.20120346322855422
   PubMed Web of Science ®Google Scholar
• Song JS, Kang CM, Kang HH, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin-induced murine pulmonary fibrosis. Exp Mol Med. 2010;42(6):465–472. doi:10.3858/emm.2010.42.6.04820498529
   PubMedGoogle Scholar
• Yin C, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest. 2013;123(5):1902–1910. doi:10.1172/JCI6636923635788
   PubMed Web of Science ®Google Scholar
• Moreno M, Bataller R. Cytokines and renin-angiotensin system signaling in hepatic fibrosis. Clin Liver Dis. 2008;12(4):825–852. doi:10.1016/j.cld.2008.07.01318984469
   PubMed Web of Science ®Google Scholar
• Hanafusa H, Ninomiya-Tsuji J, Masuyama N, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression. J Biol Chem. 1999;274(38):27161–27167.10480932
   PubMed Web of Science ®Google Scholar
• Engel ME, McDonnell MA, Law BK, Moses HL, Interdependent SMAD. JNK signaling in transforming growth factor-β-mediated transcription. J Biol Chem. 1999;274(52):37413–37420.10601313
   PubMed Web of Science ®Google Scholar
• Detlef S, Ook KY. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123(5):1887–1901. doi:10.1172/JCI6602823635787
   PubMedGoogle Scholar
• Aoudjehane L, Boelle P-Y, Bisch G, et al. Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts. Lab Invest. 2016;96(6):672. doi:10.1038/labinvest.2016.10826950484
   PubMedGoogle Scholar
• Song Y, Zhan L, Yu M, et al. TRPV4 channel inhibits TGF-β1-induced proliferation of hepatic stellate cells. PLoS One. 2014;9(7):e101179. doi:10.1371/journal.pone.010117925013893
   PubMedGoogle Scholar
• Shao X-R, Wei X-Q, Zhang S, et al. Effects of micro-environmental pH of liposome on chemical stability of loaded drug. Nanoscale Res Lett. 2017;12(1):504. doi:10.1186/s11671-017-2256-928836126
   PubMedGoogle Scholar
• Olusanya OT, Haj Ahmad RR, Ibegbu MD, Smith RJ, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018;23(4):907. doi:10.3390/molecules23040907
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi:10.3389/fphar.2015.0028626648870
   PubMed Web of Science ®Google Scholar
• Dekel R, Zvibel I, Brill S, Brazovsky E, Halpern Z, Oren R. Gliotoxin ameliorates the development of fibrosis and cirrhosis in a thioacetamide rat model. Dig Dis Sci. 2003;48(8):1642–1647.12924662
   PubMed Web of Science ®Google Scholar
• Fu M-Y, He Y-J, Lv XIA, et al. Transforming growth factor-β1 reduces apoptosis via autophagy activation in hepatic stellate cells. Mol Med Rep. 2014;10(3):1282–1288. doi:10.3892/mmr.2014.238325059289
   PubMedGoogle Scholar
• Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology. 2001;121(3):685–698.11522753
   PubMed Web of Science ®Google Scholar
• Jeong Sup S, Chun MK, Hyeon Hui K, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin-induced murine pulmonary fibrosis. Exp Mol Med. 2010;42(6):465. doi:10.3858/emm.2010.42.6.04820498529
   PubMedGoogle Scholar